A 12-page Executive Summary offering summary highlights for 22 Accountable Care Organizations and ACO solutions companies regarding their successes during the most recent MSSP performance year.
Top therapeutic areas (TAs) expected to drive biopharma market growth, 2022 to 2028
- Oncology: +$142B
- CNS (Neurology/Central nervous system): +$56B
- Endocrine: +$38B
- Immuno-modulators: +$36B
- Metabolic diseases: +$40B
- Cardiovascular: +$17B
- Blood: +$10B
- Musculo-skeletal: +$11B
- Other TAs: +$98B
- Anti-infectives: -$44B
Source: EY, How life sciences can make the right deals in a time of change, January 2024 - https://www.ey.com/en_gl/life-sciences/mergers-acquisitions-firepower-report
ACO Performance Case Studies
*By signing up for this offer you agree to receive the Accountable Care bulletin and the HealthExecWire news release bulletin.
Accountable Care
Offerings
Value-Based Payments
Offerings
Analytics
Offerings
Population Health
Offerings
Payers & Providers
Offerings